In the first placebo-controlled study of vaporized cannabis for acute migraine, patients report greater relief from pain and ...

Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will ...

Deep-pocketed investors have adopted a bullish approach towards Eli Lilly LLY, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this ...

Novo Nordisk's beaten-down valuation became too attractive to pass up, so I bought the stock earlier this year. Eli Lilly's ...

In the most recent trading session, Eli Lilly (LLY) closed at $786.92, indicating a +1.19% shift from the previous trading day.

Eli Lilly’s Zepbound transformed weight loss drug market since debut 18 months ago 4.5 million people reportedly taking Lilly ...

Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, ...

Eli Lilly and Company’s LLY stock has declined 15.7% in the past year. The first-quarter earnings miss, guidance cut and some ...

Indianapolis: Eli Lilly and Company has received approval from the U.S. Food and Drug Administration (FDA) for a label update ...

Approval was based on results from the Phase IIIb TRAILBLAZER-ALZ 6 trial, which showed that Kisunla achieved comparable ...

Adults with obesity were more likely to achieve a 10% or greater weight loss at 1 year if they continued using their ...

The symptoms can include nerve pain, emotional numbness and sexual dysfunction and can last for years after stopping the ...